CL2020002622A1 - Anticuerpos anti-cd40 para uso en la prevención del rechazo de injertos - Google Patents

Anticuerpos anti-cd40 para uso en la prevención del rechazo de injertos

Info

Publication number
CL2020002622A1
CL2020002622A1 CL2020002622A CL2020002622A CL2020002622A1 CL 2020002622 A1 CL2020002622 A1 CL 2020002622A1 CL 2020002622 A CL2020002622 A CL 2020002622A CL 2020002622 A CL2020002622 A CL 2020002622A CL 2020002622 A1 CL2020002622 A1 CL 2020002622A1
Authority
CL
Chile
Prior art keywords
antibodies
graft rejection
prevention
therapies
kits
Prior art date
Application number
CL2020002622A
Other languages
English (en)
Spanish (es)
Inventor
Pascal Espie
James Rush
Boerje Haraldsson
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2020002622A1 publication Critical patent/CL2020002622A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2020002622A 2018-04-13 2020-10-09 Anticuerpos anti-cd40 para uso en la prevención del rechazo de injertos CL2020002622A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862657172P 2018-04-13 2018-04-13
EP18208332 2018-11-26

Publications (1)

Publication Number Publication Date
CL2020002622A1 true CL2020002622A1 (es) 2021-04-16

Family

ID=66542473

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002622A CL2020002622A1 (es) 2018-04-13 2020-10-09 Anticuerpos anti-cd40 para uso en la prevención del rechazo de injertos

Country Status (13)

Country Link
US (2) US11780927B2 (https=)
EP (1) EP3774913A1 (https=)
JP (2) JP6861301B2 (https=)
KR (1) KR20200143718A (https=)
CN (1) CN111971307A (https=)
AU (1) AU2019252858A1 (https=)
BR (1) BR112020020277A2 (https=)
CA (1) CA3094600A1 (https=)
CL (1) CL2020002622A1 (https=)
IL (1) IL277828A (https=)
MX (1) MX2020010722A (https=)
TW (1) TW201943731A (https=)
WO (1) WO2019198019A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020225736A1 (en) * 2019-05-08 2020-11-12 Novartis Ag Anti-cd40 antibodies for use in treatment of t1dm and insulitis
CN116234909A (zh) * 2020-08-21 2023-06-06 上海药明生物技术有限公司 Cd40激动剂抗体和使用方法
WO2022090194A1 (en) * 2020-10-26 2022-05-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for assessing the area under the curve of an immunosuppressant and associated method and systems
EP4402174A1 (en) * 2021-09-17 2024-07-24 Novartis AG Methods for prevention of graft rejection in xenotransplantation
WO2025117849A1 (en) * 2023-11-28 2025-06-05 Eledon Pharmaceuticals, Inc. Methods and compositions for prevention of transplant rejection
WO2025184603A2 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025235683A1 (en) * 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Methods and compositions for prevention of transplant rejection
WO2025235670A1 (en) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Use of anti-cd40 ligand antibodies for immunosuppression in islet cell transplantation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
BRPI0417266B8 (pt) 2003-12-25 2021-05-25 Kyowa Hakko Kirin Co Ltd anticorpo monoclonal, seu uso e composição farmacêutica
CN101014386A (zh) * 2004-04-27 2007-08-08 诺华疫苗和诊断公司 拮抗性抗－cd40单克隆抗体及其使用方法
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
BR112012024713B1 (pt) 2010-03-31 2021-02-17 Boehringer Ingelheim International Gmbh anticorpo humanizado, seus usos e composição farmacêutica que o compreende
AR083847A1 (es) * 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US11780977B2 (en) * 2020-08-10 2023-10-10 Dover Chemical Corporation Polymer compositions having an improved printable surface and related methods

Also Published As

Publication number Publication date
MX2020010722A (es) 2020-11-06
KR20200143718A (ko) 2020-12-24
JP2021113190A (ja) 2021-08-05
WO2019198019A1 (en) 2019-10-17
CA3094600A1 (en) 2019-10-17
JP2020519634A (ja) 2020-07-02
EP3774913A1 (en) 2021-02-17
US11780927B2 (en) 2023-10-10
US20240287198A1 (en) 2024-08-29
AU2019252858A1 (en) 2020-10-08
IL277828A (en) 2020-11-30
CN111971307A (zh) 2020-11-20
TW201943731A (zh) 2019-11-16
BR112020020277A2 (pt) 2021-01-19
US20210079107A1 (en) 2021-03-18
JP6861301B2 (ja) 2021-04-21

Similar Documents

Publication Publication Date Title
CL2020002622A1 (es) Anticuerpos anti-cd40 para uso en la prevención del rechazo de injertos
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CL2019003144A1 (es) Formulaciones de anticuerpos anti-lag3 y co-formulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
AR114283A1 (es) Receptores quiméricos de dll3 y métodos para su uso
CO2018011804A2 (es) Receptores quiméricos de flt3 y métodos de uso de los mismos
CL2019002011A1 (es) Anticuerpos anti-tgf-beta y su uso.
CO2018003500A2 (es) Anticuerpos anti-pd-1 y composiciones
MX2024000348A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
CL2017000885A1 (es) Anticuerpos anti-ox40 humanizados y usos de los mismos
MX2021007768A (es) Anticuerpos anti-ctla4 y metodos de uso de los mismos.
JOP20170170B1 (ar) صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
MX2022015631A (es) Anticuerpos anti-cd40 humanizados y usos de los mismos.
MX2023005879A (es) Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
MX2021013631A (es) Anticuerpos anti-cd40 para el uso en el tratamiento de t1dm e insulitis.
PE20181005A1 (es) Anticuerpos biespecificos contra el a- beta humano y el receptor de transferrina humano y metodos de uso
EA201791554A1 (ru) Биспецифичные антитела против cd3 и cd20
MX2019007554A (es) Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso.
AR103726A1 (es) Cristales de anticuerpos monoclonales anti-pd-1 humanos
MX2017002382A (es) Metodos para tratar el mieloma multiple con compuestos imunomodulares en combinacion con anticuerpos.
MX2020003605A (es) Manipulación del metabolismo de triptamina.
CL2020001123A1 (es) Anticuerpos anti-cd40 para el uso en el tratamiento del síndrome de sjögren.
EA201691634A1 (ru) Способы лечения отторжения трансплантата с использованием доменного антитела, направленного против cd40l
MX2018005589A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.